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Introduction: Neoadjuvant systemic therapy of primary breast cancer (PBC) patients offers the possibility to
monitor treatment response. However, patients might have metastatic relapse despite achieving a pathologic
complete response (pCR). This indicates that local response to therapy must not be representative for systemic
treatment efficacy. Therefore, the aim of this study was to compare local response with systemic tumor cell
dissemination by determining the presence of disseminated tumor cells (DTCs), including apoptotic tumor cells, in
the bone marrow (BM) of PBC patients after neoadjuvant chemotherapy (NACT).
Methods: DTCs were detected by immunocytochemistry (pancytokeratin antibody A45-B/B3) and cytomorphology
(DTC status). The presence of apoptotic tumor cells was determined by using the M30 antibody (M30 status). This
antibody detects a neo-epitope that is expressed only during early apoptosis.
Results: BM aspirates from 400 PBC patients that had completed NACT were eligible for this study. Of these, 167 (42%)
patients were DTC positive (DTC status). The M30 status was investigated in 308 patients. Apoptotic (M30-positive) tumor
cells were detected in 89 (29%) of these. Whereas the DTC status was not correlated (P = 0.557) to local treatment
response (that is, pCR or a clinical complete/partial response), the presence of M30-positive tumor cells was significantly
higher in patients that responded to therapy (P = 0.026). Additionally, DTC-positive patients were at an increased risk for
disease relapse (hazard ratio, 1.87; 95% CI, 1.11 to 3.15; P = 0.019).
Conclusion: The presence of DTC is independent of therapy response of the primary tumor. As patients that are DTC
positive after NACT have an unfavorable outcome, they might benefit from additional systemic treatment.Introduction
Neoadjuvant chemotherapy (NACT) aims to reduce
tumor mass and has become a standard treatment in
primary breast cancer (PBC) patients. Initially, it was
used to treat locally advanced and nonoperable tumors.
Currently, NACT is also offered to patients with resect-
able tumors, as no differences between NACT and adju-
vant treatment in terms of overall survival and the
probability of disease relapse are evident [1,2]. In these* Correspondence: andreas.hartkopf@med.uni-tuebingen.de
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reproduction in any medium, provided the orpatients, NACT aims to facilitate breast-conserving sur-
gery. Moreover, NACT offers the possibility of moni-
toring the primary tumor’s response to treatment.
This in vivo chemosensitivity testing helps clinicians to
choose for appropriate therapy options in case of recur-
rent disease [3].
Breast cancer might relapse even years after successful
treatment of the primary tumor. Accordingly, the disease
must have the ability to persist in secondary sites of the
body, a phenomenon that is called minimal residual dis-
ease (MRD). To prevent metastatic regrowth effectively,
MRD has to be eradicated before it becomes clinically
evident [4,5]. Monitoring of the treatment success againstl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of PBC patients.
During NACT, the success of systemic treatment is cur-
rently determined locally (that is, by reassessing the pri-
mary tumor size). It is, however, not clear whether therapy
response of the primary tumor is representative for the en-
tire tumor burden (that is, for systemic treatment efficacy).
Although pathologic complete response (pCR) of the pri-
mary tumor is associated with a favorable prognosis [6-9],
subgroups of patients seem to not have a prognostic benefit
from achieving a pCR. Minckwitz et al. recently evaluated
the clinical value of pCR as related to intrinsic breast can-
cer subtypes and found that the primary tumor’s response
to NACT has no impact on prognosis in luminal A as well
as in luminal B/HER2-positive patients [10]. Other reports
indicate that 15% to 25% of all patients receiving NACT
will develop metastatic disease despite a pCR [11-15].
Therefore, the persistence of MRD after NACT may be in-
dependent of the success of primary tumor treatment.
It has been hypothesized that disseminated tumor cells
(DTCs) in the bone marrow (BM) of PBC patients are a
surrogate of MRD [16]. DTCs are detected in 13% to
40% of the cases and are an independent predictor of
poor prognosis [17-25]. In addition, several studies have
indicated that the presence of DTCs after adjuvant ther-
apy predicts an increased risk of disease relapse [26-31].
However, only few smaller studies have investigated the
fate and prognostic relevance of DTCs after NACT, with
inconsistent results [32-35].
The aim of this study was to compare local with sys-
temic response to NACT in a large cohort of PBC pa-
tients. For this purpose, we evaluated the prevalence of
DTCs and apoptotic tumor cells at the time of surgery
and compared our findings with response of the primary
tumor. Moreover, we determined the prognostic rele-
vance of DTC persistence after NACT.
Methods
Study population
Patients with PBC (cT1-cT4, cN0-cN2) who were treated
with NACT and underwent surgery at the DepartmentTable 1 Neoadjuvant systemic treatment regimens
Treatment regimen
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d)
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × doc
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 4 × doc
4 × epirubicin/cyclophosphamide (90/600 mg/m2 q21d) followed by 12 × pac
4 × epirubicin/docetaxel (60/75 mg/m2 q21d)
6 × doxorubicin/cyclophosphamide/docetaxel (50/500/75 mg/m2 q21d)
6 × gemcitabine d1 + 8/epirubicin d1/docetaxel d1 (800/90/75 mg/m2 q21d)
aLoading dose: 8 mg/kg.of Gynecology and Obstetrics at Tuebingen University
Hospital, Germany, between January 2001 and January
2012 were eligible for this retrospective analysis. Exclu-
sion criteria were metastatic or recurrent disease, bilateral
breast cancer, and a previous history of secondary malig-
nancy. All patients provided written informed consent for
BM aspiration, and the analysis was approved by the ethics
committee of the University of Tuebingen (560/2012R).
Treatment regimens are shown in detail in Table 1.
Determination of response to treatment
Pathologic complete response (pCR) was defined as the
absence of residual invasive cancer on pathologic evalu-
ation of resected breast specimens and lymph nodes [36].
For patients that did not achieve a pCR, response to treat-
ment was determined by physical examination and imaging
tests. The preferred imaging modality was ultrasound.
However, if ultrasound appeared not to provide valid re-
sults, other imaging tests were used, with the following
priority: MRI, mammography. The effect of NACT was
graded according to the World Health Organization cri-
teria [37]. Partial remission was defined as a reduction of
the primary tumor area by 50% or more (multiplication of
longest diameter by the greatest perpendicular diameter; in
patients with multifocal or multicentric disease, the lesion
with the largest diameters was used), and also includes pa-
tients with clinical complete remission (disappearance of
all known disease) that did not achieve a pCR. Progressive
disease was defined as the development of new, pre-
viously undetected lesions or an increase in the diam-
eter product of a preexisting lesion by more than 25%
after at least two treatment cycles. Stable disease was de-
fined as anything between partial remission and progres-
sive disease. To determine response to NACT, we defined
patients with pCR or partial remission as responders,
whereas those with stable or progressive disease were de-
fined as nonresponders.
Bone marrow status and immunohistochemistry
Approximately 3 to 4 weeks after NACT, 10 to 20 ml of
BM aspirates was collected during surgery. All samplesn
37
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etaxel (175 mg/m2 q21d) + 4 × Herceptin (6 mg/kg q21d)a 26
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[38]. In brief, mononuclear cells were separated with dens-
ity centrifugation (Ficoll, 1.077 g/ml; Biochrom, Germany),
spun down onto a glass slide (Hettich cytocentrifuge;
Germany) and fixed in 4% formalin. The presence of DTC
(DTC status) was evaluated by immunostaining with the
DAKO Autostainer (Dako, Denmark), the monoclonal
mouse A45-B/B3 antibody directed against pancytokeratin
(Micromet, Germany), and the DAKO-APAA detection
kit (Dako). For each patient, two slides (2 × 106 cells)
were automatically scanned by using the ACIS imaging
system (ChromaVision; Medical Systems Inc., San Juan
Capistrano, CA, USA) and evaluated based on consensus
recommendations for standardized tumor-cell detection
and the criteria of the European ISHAGE Working group
[39,40]. An additional slide was stained by using an unspe-
cific isotype-matched antibody. Moreover, with each batch
of samples, leukocytes from healthy volunteers served as
negative control, and the cell lines MCF-7 and SKBR-3
were used as positive control.
To evaluate the specificity of our method for DTC-
detection, we analyzed BM samples of 100 individuals
without evidence of malignant disease for the presence
DTCs, earlier [28]. Of these patients, one harbored DTCs.
To detect apoptotic tumor cells (M30 status), add-
itional slides were stained with the M30-antibody (Roche
Applied Science, Mannheim, Germany) and analyzed by
using the previously described detection method. The
M30-antibody is directed against an epitope expressed
only after caspase cleavage of CK18 during early apop-
tosis [41,42]. Identification of apoptotic tumor cells was
based on positive M30-staining and cytomorphologic cri-
teria, as described elsewhere [34,43,44].
Statistical analysis
Associations between categoric variables (DTC status/
M30 status and patient characteristics) were analyzed by
using the χ2 test. To determine survival, times from BM
aspiration to any recurrence of disease (disease-free sur-
vival, DFS) and to death of any cause (overall survival, OS),
respectively, were investigated separately. If no event oc-
curred, data were censored at last follow-up. The influence
of the DTC status/M30 status on survival was determined
in a univariate analysis and described by hazard ratio (HR)
and the corresponding 95% confidence interval (CI).
Kaplan-Meier curves were plotted and compared with the
log-rank test. For multivariate analysis, a Cox proportional
regression model was used. Variables were entered step-
wise backward, and a significance level of 0.1 was used to
exclude a variable from the model. The initial model in-
cluded menopausal status, histology, grading, nodal status
before/after NACT, tumor size before/after NACT, ER/PR/
HER2 status, and the DTC status. The effect of each vari-
able was evaluated by using the Wald test and described byHR and the corresponding 95% CI. All statistical tests were
carried out with PASW Statistics 20 (SPSS Inc., Chicago,
IL, USA) and reported two-sided with significance levels
set to P < 0.05.
Results
Patient characteristics
In total, 400 patients were included in the analysis. De-
tails of patient characteristics are presented in Table 2.
The median age was 49 (range, 21 to 87) years, and most
women were premenopausal (229, 57%). The predomin-
ant histology was invasive ductal carcinoma (324, 81%).
Most patients had a tumor grade II (260, 65%). Clinical
tumor size before NACT was available in 385 patients,
cT1-2 in 208 patients (53%) and cT3-4 in 177 patients
(46%). The clinical nodal status before NACT was avail-
able in 376 patients, negative in 106 patients (28%) and
positive in 270 patients (72%). After NACT, 90 patients
(23%) had ypT0 tumors, 169 patients (42%) had ypT1
tumors, and 141 patients (35%) had ypT2 to 4 tumors.
The nodal status after NACT was ypN0 in 197 (49%)
and ypN1-3 in 203 patients (51%); 253 patients (63%)
were ER-positive, 263 were PR-positive (66%), and 306
were HER2-negative (77%). 373 patients (93%) responded
to NACT (75 patients had a pCR and 298 patients a par-
tial remission), and 27 patients (7%) were nonresponders
(stable and progressive disease was observed in 19 and
eight patients, respectively).
Prevalence of DTCs and apoptotic tumor cells
After NACT, DTCs were detected in the BM of 167
(42%) patients (Table 2). A positive DTC status was ob-
served more frequently in PR-negative patients (49%)
than in PR-positive patients (38%) (P = 0.036). Except for
the PR status, no significant association was noted be-
tween the DTC status and any established prognostic fac-
tor. Importantly, the presence of DTC was not reflected by
the primary tumor response to NACT (P = 0.912).
BM samples of 308 patients were additionally screened
for M30-positive apoptotic tumor cells. M30-positive cells
were detected in 89 (29%) of these patients (Table 2). A
significant association was found between the M30 status
and the ER (P = 0.041) and PR status (P = 0.001), respect-
ively. Also, patients that were nodal positive before NACT
were more likely to be M30 positive (P = 0.020). Moreover,
the prevalence of apoptotic tumor cells was significantly
higher in patients that had received NACT including tras-
tuzumab (P = 0.002). Importantly, there was a significant
association between the presence of apoptotic tumor cells
and response to NACT (P = 0.026).
As demonstrated in Table 3, 12 of 308 patients
(4%) harbored apoptotic tumor cells only (M30-positive/
DTC-negative), whereas in 77 of 308 patients (25%)
both, apoptotic tumor cells and DTC, were detected (M30
Table 2 Patient characteristics and the prevalence of DTC and apoptotic (M30-positive) tumor cells
DTC Apoptotic tumor cells
n/total (%) P value n/total (%) P value
Total 167/400 (42) 89/308 (29)
Menopausal status
Premenopausal 100/229 (44) 54/176 (31)
Postmenopausal 67/171 (39) 0.368 35/132 (27) 0.425
Histology
Invasive ductal 130/324 (40) 81/258 (31)
Invasive lobular 32/66 (49) 7/44(16)
Other 2/6 (33) 0/3 (0)
Missing 3/4 (75) 0.418d 1/3 (33) 0.060d
Tumor grade
Grade 2 105/260 (40) 51/197 (26)
Grade 3 56/120 (47) 32/94 (34)
Missing 6/20 (30) 0.249d 6/17 (35) 0.150 d
Tumor size before NACT
cT1-2 88/208 (42) 46/167 (28)
cT3-4 78/177 (41) 40/128 (31)
Missing 6/15 (40) 0.833 d 3/13 (23) 0.488 d
Nodal status before NACT
cN0 41/106 (39) 14/75 (19)
cN1 115/270 (43) 70/213 (33)
Missing 11/24 (26) 0.488 d 5/20 (25) 0.020 d
Tumor size after NACT
ypT0 32/90 (36) 25/74 (34)
ypT1 67/169 (40) 40/133 (30)
ypT2-4 68/141 (48) 0.125 24/101 (24) 0.325
Nodal status after NACT
ypN0 76/197 (39) 43/149 (29)
ypN1-3 91/203 (45) 0.205 46/159 (29) 0.989
ER status
Negative 67/147 (46) 42/118 (36)
Positive 100/253 (40) 0.237 47/190 (25) 0.041
PR status
Negative 67/137 (49) 43/105 (41)
Positive 100/263 (38) 0.036 46/203 (23) 0.001
HER2 status
Negative 133/306 (43) 69/237 (29)
Positive 34/94 (36) 0.210 20/71 (28) 0.878
Response to NACT
Responderb 156/373 (42) 87/285 (31)
Nonresponderc 11/27 (41) 0.912 2/23 (9) 0.026
Pathologic remission
pCR 26/75 (35) 18/60 (30)
No pCR 141/325 (43) 0.168 71/248 (29) 0.833
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Table 2 Patient characteristics and the prevalence of DTC and apoptotic (M30-positive) tumor cells (Continued)
HER2-directed NACTa
No 24/68 (35) 8/48 (17)
Yes 10/26 (39) 0.775 12/23 (52) 0.002
NACT, neoadjuvant systemic therapy. aOnly HER2-positive patients were taken into account. bpCR or partial response. cStable or progressive disease.
dP value (χ2 test) not including missing data.
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patients responded to NACT. Of the 77 M30-positive/
DTC-positive patients, 75 (97%) responded to NACT.
No tumor cells (M30-negative/DTC-negative) were de-
tected in 179 of 308 patients (58%), and only DTC (M30-
negative/DTC-positive) in 40 of 308 patients (13%).
Of these patients, 164 (92%) and 34 (85%), respectively,
responded to NACT. A subgroup analysis revealed that
the presence of apoptotic tumor cells was significantly as-
sociated with response to NACT, not only in the whole
collection, but also in the subgroup of DTC-positive
patients (75 of 109 (69%) DTC-positive responders were
M30-positive, whereas only two of eight (25%) DTC-
positive nonresponders were M30-positive; P = 0.012).
Survival analysis
Follow-up data for the calculation of DFS and OS were
available in 330 and 376 patients, respectively. The median
follow-up was 45.34 months for DFS and 54.46 months
for OS. Univariate analysis revealed no impact of the M30
status on DFS (P = 0.162) and OS (P = 0.097). Also, in a
subgroup analysis regarding only DTC-positive patients,
the M30status was associated neither with DFS (P = 0.402)
nor with OS (P = 0.152).
There was a significant difference between DFS of DTC-
negative versus DTC-positive patients (Figure 1): 30 events
occurred in the group of 201 DTC-negative patients and
31 events in the group of 129 DTC-positive patients (HR,
1.87; 95% CI, 1.11 to 3.15; P = 0.019). However, the DTC
status had no influence on OS (27 events occurred in the
group of 222 DTC-negative patients, and 25 events, in the
group of 154 DTC-positive patients, P = 0.116).
In multivariate analysis (Table 4), independent factors
of DFS were DTC status, nodal status after NACT, andTable 3 Response to NACT as related to the detection of
DTCs and apoptotic (M30-positive) tumor cells
Apoptotic
tumor cells
DTC Total Respondera Nonresponderb
n = 308 n (%) = 285 (92) n (%) = 23 (8)
+ - 12 12 (100) 0 (0)
+ + 77 75 (97) 2 (3)
- - 179 164 (92) 15 (8)
- + 40 34 (85) 6 (15)
(P = 0.068, χ2 test). apCR or partial response; bstable or progressive disease.response to NACT. Independent factors of OS were
tumor grade and response to NACT.
Discussion
In the past decade, NACT has become an increasingly
important strategy to treat PBC patients. Many clinical
trials on systemic breast cancer treatment are currently
conducted in the neoadjuvant situation, by using re-
sponse to therapy as an early and easy-to-perform study
end point and a surrogate for prognosis. Although re-
sponse to NACT is associated with disease-free and
overall survival some subgroups of patients do not
benefit from achieving pCR and approximately 15% to
25% of the patients may develop metastatic disease despite
pCR [10-15]. This indicates that the disease must have the
ability to persist in secondary sites of the body and that
local response to therapy is not necessarily representative
of systemic response. Because micrometastatic spread
of DTCs into the BM is a promising marker of disease
persistence, this large retrospective analysis aimed to
compare local response to NACT, as reflected by the pri-
mary tumor, with systemic response, as reflected by the
presence of DTC and apoptotic tumor cells. We more-
over determined the impact of the DTC status after
NACT on prognosis.
DTCs were detected in 42% of the patients. An ex-
planation for this comparatively high prevalence is that
most women had initially advanced stages with nodal in-
volvement. In general, these patients tend to have higher
positivity rates in BM aspirates [17,18,20-22,34,45]. Im-
portantly, the presence of DTCs after NACT was not
reflected by response of the primary tumor, indicating
that local response to treatment is independent of sys-
temic treatment efficacy. This observation is in line with
previous reports and most likely due to altered genomic
characteristics between CTC/DTC and primary tumor
tissue of the same patient [32,33,35,46]. For example,
phenotypic changes like HER2-amplification or epithelial-
to-mesenchymal transition (EMT) can occur during tumor
cell dissemination [47,48]. Moreover, a large proportion of
DTCs in breast cancer patients display stem cell-like fea-
tures, such as ALDH1 positivity or presence of CD44 and
absence of CD24 [49]. The cancer stem-cell hypothesis
postulates that these cells not only might initiate tumori-
genesis and metastatic growth, but also contribute import-
antly to therapy resistance [50].
Figure 1 Disease-free (DFS) and overall (OS) survival of DTC-negative versus DTC-positive patients.
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induced tumor regression, and several studies have re-
ported on the detection of single apoptotic cells in
either peripheral blood or BM of breast cancer patients
[34,51-53]. To detect apoptotic cells, we and others used
immunocytochemical staining with the M30-antibody
[34,51]. The neo-epitope M30 is expressed by caspase
cleavage of CK18 only during early apoptosis. Interest-
ingly, serum levels of the CK fragment were shown to
correlate with tumor load and prognosis during breast
cancer chemotherapy [54]. In line with our previously
presented results, the presence of apoptotic tumor cells
was associated with local therapy response [34].
To differentiate between DTCs and false-positive cells,
morphologic evaluations were performed as recom-
mended by the ISHAGE Working Group. Therefore,
cells with typical morphologic signs of apoptosis (cellular
shrinkage, membrane blebbing, nuclear condensation,





Positive versus negative 1.87 (1.09 to 3.20)
Tumor grade
Grade III versus Grade II NS
Nodal status after NACT
ypN1-3 versus ypN0 2.22 (1.18 to 4.19)
Response to NACT
Nonrespondera versus
responderb 2.88 (1.32 to 6.31)
PFS, progression-free survival; OS overall survival; CI, confidence interval; NS, not signifthe majority of DTC-positive patients also harbored
M30-positive cells, we believe that tumor cells in the
BM represent a heterogeneous population of apoptotic and
nonapoptotic cells. However, we cannot exclude that some
DTCs might be M30 positive (that is, apoptotic), as the
M30 status was evaluated on additional slides, and a
double-staining procedure was not performed for tech-
nical reasons. Moreover, A45-B/B3 detects CK8, CK18,
and CK19, whereas M30 detects a neoepitope of CK18,
only. Thus, differences in the results between these two
antibodies might be biased by different CK-expression
patterns.
Principally, two different mechanisms would explain
the source of apoptotic tumor cells in BM aspirates.
These could be the result of a passive cell shedding from
the primary tumor during NACT [35] and therefore re-
flect local response to NACT. The association between
local treatment response and the M30 status we ob-
served supports this hypothesis. Also, advanced tumorOS
P value HR P value
(95% CI)
0.027 NS
3.04 (1.66 to 5.55) <0.001
0.014 NS
0.008 2.42 (1.04 to 5.64) 0.041
icant; HR, hazard ratio. aStable or progressive disease; bpCR or partial response.
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tumor-cell turnover, and a higher breast cancer grade
was recently shown to result in increased shedding of
apoptotic tumor cells into the circulation [51,55]. In
accordance, we found that patients at advanced stages
(nodal positive) before the beginning of NACT as well as
hormone-receptor-negative patients were more likely to
present with apoptotic tumor cells in BM.
Conversely, DTCs that are the result of an active pre-
metastatic process might undergo apoptosis, caused by
systemic efficacy of NACT. However, chemotherapy is
often unable to eradicate nonproliferating DTCs [27]. In-
deed, we could not find an association between the pres-
ence of apoptotic cells and survival. A subgroup analysis,
regarding the impact of the M30 status on survival in
DTC-positive patients, confirmed this observation. Some
authors therefore suggested the use of bisphosphonates
as an alternative for cell-cycle-independent treatment of
DTC-positive patients [56-58]. Others indicate that tar-
geted therapy might be more appropriate than con-
ventional chemotherapeutic regimens to eradicate MRD
successfully [27,59,60]. Interestingly, we found that the
prevalence of apoptotic tumor cells in patients that re-
ceived trastuzumab was increased. This indicates a specific
action of HER2-directed therapy against a significant sub-
population of DTCs. We recently found, in a large cohort
of PBC patients, that about half of the DTC-positive
patients harbor HER2-positive DTCs, independent of
the HER2 status of the primary tumor [48]. The clinical
value of HER2-directed therapy to treat MRD will
be evaluated within the forthcoming “TREAT CTC”
study (NCT01548677). In this trial, HER2-negative PBC
patients with one or more CTCs after (neo)adjuvant
chemotherapy will be randomized to receive trastuzumab
treatment or not.
In PBC patients that have not been treated systemic-
ally before BM aspiration, the detection of DTCs has
clearly proven to be of prognostic relevance, whereas the
role of DTC detection after NACT is less well described
[17-25,32,33]. Hall et al. [33] recently conducted a study
on 95 PBC patients that were treated with neoadjuvant
chemotherapy and found that DTC persistence is associ-
ated with breast-cancer-specific survival. Mathiesen et al.
[32] evaluated the presence of DTC in the BM before, dir-
ectly after (at surgery), and 12 months after NACT [32].
Probably due to the considerably low number of patients
(n = 69), the authors found no impact of the DTC status
directly after NACT on survival. In contrast to the results
presented by Mathiesen et al., our study demonstrates an
independent prognostic value of DTC detection after
NACT. Of note, it would be interesting to evaluate the
prognostic relevance of DTC persistence in patients with
luminal B/HER2-positive or luminal A tumors separately,
as pCR is not predictive of survival in these subgroups[10]. However, the number of patients was too low to per-
mit such an analysis.
Next to the herein investigated role of the DTC status
after NACT, promising data exist on DTC persistence in
PBC during or after adjuvant treatment [28,29,31,32]. As
these studies could also demonstrate an independent
prognostic impact in patients that have received systemic
therapy, the DTC status might be a marker of treatment
failure and is likely to indicate patients that are in need of
additional treatment. In the Norwegian SATT study
(NBCG9), 72 PBC patients that were DTC positive after
anthracycline-containing adjuvant chemotherapy received
secondary docetaxel treatment, and a majority (79%) expe-
rienced disappearance of DTCs [61]. However, the clinical
relevance of these results is not clear, as follow-up is
still ongoing.
We could not find a prognostic impact of DTC deter-
mination after NACT on OS. Interestingly, a subgroup
analysis revealed that in pretherapeutic clinical tumor
stage III patients, the DTC status was prognostic for
DFS and also OS, whereas in stage I to II patients, no
impact of the DTC status on survival was found (data not
shown). This observation is in accordance with our re-
cent analysis on 1,345 clinically nodal-negative PBC pa-
tients [62]. In that study, the DTC status had also no
impact on survival.
As BM sampling is a comparatively invasive proced-
ure, recent reports have focused on the detection of
CTC in the peripheral blood of PBC patients [63-65].
Whereas CTC detection in metastatic breast cancer pa-
tients has proven to be of prognostic relevance [66-68],
their role in PBC is less well described, and results on an
association between CTC and response to NACT or
prognosis are inconclusive [60,69-71]. This is probably
owing to methodologic differences and a lower sensitiv-
ity of CTC analysis [25]. Recently, Molloy et al. [72]
found, in 733 PBC patients, that CTC detection by use
of a PCR-based assay was highly associated with the
presence of DTCs, and that both DTC and CTC detec-
tion were predictive of survival. Further trials should
therefore evaluate the clinical value of DTC/CTC enu-
meration in the neoadjuvant situation, especially as CTC
detection offers the possibility of serial blood sampling
during the course of therapy.
Conclusions
The detection of DTCs in the bone marrow of PBC pa-
tients is considered as a marker of systemic disease. In
line with recent smaller studies, we found that the pres-
ence of DTCs after NACT was independent of the pri-
mary tumor response to treatment. As the DTC status
was moreover associated with an unfavorable outcome,
even patients with pCR but DTC persistence after NACT
might benefit from additional adjuvant therapy. Moreover,
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population of apoptotic and nonapoptotic cells. Although
the prevalence of apoptotic tumor cells was increased in
patients that responded to NACT, no influence of apop-
totic tumor cell detection was found on prognosis. The
clinical relevance of monitoring apoptosis during therapy
remains unclear. Further characterization of DTCs and
clinical trials are needed to understand the biologic mech-
anism of tumor cell persistence and to determine their im-
pact on optimizing (neo)adjuvant breast cancer treatment.
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